Influenza continues to baffle humans by its constantly changing nature. The twenty-first century has witnessed considerable advances in the understanding of the influenza viral pathogenesis, its synergy with bacterial infections and diagnostic methods. However, challenges continue: to find a less expensive and more reliable point-of-care test for use in developing countries, to produce more efficacious antiviral drugs, to explore ways to combat emerging antiviral resistance and to develop vaccines that can either be produced in a shorter production time or can overcome the need for annual matching with the circulating influenza strains. Most importantly for India, as a nation that suffered the highest mortality in the influenza pandemic 1918, there is an urgent need to gear up our existing preparedness for the next pandemic which is capable to hit at any moment in time.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Chandra S, Eva K-NE. The evolution of pandemic influenza: evidence from India, 1918–19. BMC Infect Dis. 2014;14:510.
Jester B, Uyeki T, Jernigan D. Readiness for responding to a severe pandemic 100 years after 1918. Am J Epidemiol. 2018;187:2596–602.
Lowen AC, Steel J. Roles of humidity and temperature in shaping influenza seasonality. J Virol. 2014;88:7692–5.
Ng S, Gordon A. Influenza burden and transmission in the tropics. Curr Epidemiol Rep. 2015;2:89–100.
National Centre for Disease Control. Seasonal Influenza H1N1. Available at: https://ncdc.gov.in/index4.php?lang=1&level=0&linkid=119&lid=276. Accessed 2nd August 2019.
Chadha MS, Potdar VA, Saha S, et al. Dynamics of influenza seasonality at sub-regional levels in India and implications for vaccination timing. PLoS One. 2015;10:e0124122.
Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis. 2003;37:1094–101.
A revision of the system of nomenclature for influenza viruses: a WHO memorandum. Bull World Health Organ. 1980;58:585–91.
Kumlin U, Olofsson S, Dimock K, Arnberg N. Sialic acid tissue distribution and influenza virus tropism. Influenza Other Respir Viruses. 2008;2:147–54.
Mansfield KG. Viral tropism and the pathogenesis of influenza in the Mammalian host. Am J Pathol. 2007;171:1089–92.
Camp JV, Bagci U, Chu YK, et al. Lower respiratory tract infection of the ferret by 2009 H1N1 pandemic influenza A virus triggers biphasic, systemic, and local recruitment of neutrophils. J Virol. 2015;89:8733–48.
Herold S, Becker C, Ridge KM, Budinger GR. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur Respir J. 2015;45:1463–78.
Wikramaratna PS, Sandeman M, Recker M, Gupta S. The antigenic evolution of influenza: drift or thrift? Philos Trans R Soc Lond Ser B Biol Sci. 2013;368:20120200.
Yewale V, Dharmapalan D. Complications and prognosis of influenza. In: Rao I, editor. Influenza: Complete Spectrum - II - ECAB. New Delhi: Elsevier Health Sciences; 2011. p. 1–20.
Vander Sluijs KF, van der Poll T, Lutter R, Juffermans NP, Schultz MJ. Bench-to-bedside review: bacterial pneumonia with influenza - pathogenesis and clinical implications. Crit Care. 2010;14:219.
Rowe HM, Meliopoulos VA, Iverson A, Bomme P, Schultz-Cherry S, Rosch JW. Direct interactions with influenza promote bacterial adherence during respiratory infections. Nat Microbiol. 2019;4:1328–36.
Magee H, Goldman RD. Viral myositis in children. Can Fam Physician. 2017;63:365–8.
Vemula SV, Zhao J, Liu J, Wang X, Biswas S, Hewlett I. Current approaches for diagnosis of influenza virus infections in humans. Viruses. 2016;8:96.
Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis. 2009;48:S3–13.
Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. 2012;12:240–8.
CDC. Influenza Antiviral Medications: Summary for Clinicians. Available at: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. Accessed 26th Dec 2019.
Mishin VP, Patel MC, Chesnokov A, et al. Susceptibility of influenza a, B, C, and D viruses to baloxavir. Emerg Infect Dis. 2019;25:1969–72.
Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54:2575–82.
Houser K, Subbarao K. Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015;17:295–300.
Sautto GA, Kirchenbaum GA, Ross TM. Towards a universal influenza vaccine: different approaches for one goal. Virol J. 2018;15:17.
Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68:e1–47.
WHO. Global Influenza Strategy 2019-2030. Geneva: World Health Organization; 2019. Available at: https://apps.who.int/iris/bitstream/handle/10665/311184/9789241515320-eng.pdf?ua=1.
Conflict of Interest
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Dharmapalan, D. Influenza. Indian J Pediatr (2020). https://doi.org/10.1007/s12098-020-03214-1
- Influenza vaccines